Loading…
CMMB
Chemomab Therapeutics Ltd.
NASDAQ· Healthcare· Biotechnology· CUSIP 16385C203
$2.71-0.37%Price as of Aug 29, 18:44 UTC · updated once a day, after the close
Key metrics
- Market cap
- $19.86M
- P/E
- —
- Forward P/E
- —
- P/B
- 2.3x
- Dividend yield
- —
- Payout
- —
- EPS
- -$0.96
- ROE
- -82.17%
- Profit margin
- 0.00%
- Revenue growth
- —
- Beta
- 0.66
- 52-week high
- $3.58
- 52-week low
- $1.35
History
How the company evolved, year by year. Revenue and debt come from the annual reports — for most companies, the 10-K filings with the SEC since 2009; dividends from the payments themselves.
The bars are a balance on the closing date; the lines are what happened during the year. Revenue above equity is ordinary, not an anomaly — it means the company turns its capital over more than once a year.
Investors holding this
Major managers that reported this stock in their latest 13F.
Price over time
▼ -94.6% over 5Y.
today you would have $48.74▼ -95.1%
Dividends reinvested, splits accounted for. Past prices say what happened, not what will.
Indicators, year by year
The last 4 closed years. Each multiple uses that year’s closing price and that year’s reported numbers — not today’s. The range is set by the annual reports on record.
| Indicator | Median | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Year-end price | $1.65 | $7.24 | $2.04 | $12.80 | |
| P/B | 77.5x | 77.0x | 201.7x | 34.1x | 78.1x |
| EPS | -$1.44 | -$3.44 | -$8.24 | -$9.68 | |
| ROE | -89.67% | -72.93% | -103.01% | -142.50% | -76.32% |
Median, not average: a single year of near-zero profit produces a P/E of 400 and would drag an average on its own. P/E years above 200x are left out, the same cut the fair price uses — so this median matches the “its own history” method below. Price and EPS have no median: they are series that grow.
Others in the same sector
Companies of similar size in Healthcare, for comparison. The columns are the same ones above, in the same order.
| Stock | Price | P/E | P/B | Dividend yield | ROE | Market cap |
|---|---|---|---|---|---|---|
| QNTMQuantum Biopharma Ltd. | $3.08 | — | 2.9x | — | -621.46% | $19.77M |
| NEUPNeuphoria Therapeutics Inc. | $3.76 | — | 0.7x | — | -62.90% | $20.32M |
| CCMConcord Medical Services Holdings Ltd | $4.76 | — | — | — | -21.88% | $20.67M |
| AKTXAkari Therapeutics Plc | $10.70 |
About the company
Chemomab Therapeutics Ltd., a clinical-stage biotechnology company, focuses on the discovery and development of therapeutics for the treatment of fibrotic and inflammatory diseases. Its lead product candidate is nebokitug, a humanized monoclonal antibody that attenuates the basic function of CCL24 as a regulator of major inflammatory and fibrotic pathways, which has completed phase 2 clinical trial for treating primary sclerosing cholangitis, as well as in phase 2 clinical trial to treat systemic sclerosis. The company was founded in 2011 and is based in Tel Aviv-Yafo, Israel.
- Tel Aviv-Yafo, Israel
Company description provided by Yahoo Finance.